行情

ARWR

ARWR

箭头制药
NASDAQ

实时行情|Nasdaq Last Sale

28.12
-2.47
-8.07%
盘后: 27.88 -0.24 -0.85% 19:24 03/27 EDT
开盘
29.83
昨收
30.59
最高
30.15
最低
27.95
成交量
130.20万
成交额
--
52周最高
73.72
52周最低
17.30
市值
28.59亿
市盈率(TTM)
52.30
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ARWR价格均价为61.67,最高价位81.00,最低价为29.00。

EPS

ARWR 新闻

更多
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 2天前
  • Blair likes Incyte in premarket analyst action
  • Seeking Alpha - Article · 4天前
  • Adapting A Portfolio In A Crisis
  • Seeking Alpha - Article · 4天前
  • Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Insider Monkey · 03/20 18:15

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

ARWR 简况

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
展开

微牛提供Arrowhead Pharmaceuticals Inc(NASDAQ-ARWR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ARWR股票新闻,以帮助您做出投资决策。